Search Results - "Feldman, Howard H"

The "rights" of precision drug development for Alzheimer's disease by Cummings, Jeffrey, Feldman, Howard H, Scheltens, Philip

“…There is a high rate of failure in Alzheimer's disease (AD) drug development with 99% of trials showing no drug-placebo difference. This low rate of success…”
Get full text

Revising the definition of Alzheimer's disease: a new lexicon by Dubois, Bruno, Prof, Feldman, Howard H, Prof, Jacova, Claudia, PhD, Cummings, Jeffrey L, MD, DeKosky, Steven T, Prof, Barberger-Gateau, Pascale, MD, Delacourte, André, PhD, Frisoni, Giovanni, Prof, Fox, Nick C, Prof, Galasko, Douglas, Prof, Gauthier, Serge, Prof, Hampel, Harald, Prof, Jicha, Gregory A, MD, Meguro, Kenichi, MD, O'Brien, John, DM, Pasquier, Florence, Prof, Robert, Philippe, Prof, Rossor, Martin, Prof, Salloway, Steven, Prof, Sarazin, Marie, MD, de Souza, Leonardo C, MD, Stern, Yaakov, Prof, Visser, Pieter J, MD, Scheltens, Philip, Prof

“…Summary Alzheimer's disease (AD) is classically defined as a dual clinicopathological entity. The recent advances in use of reliable biomarkers of AD that…”
Get full text

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria by Dubois, Bruno, Prof, Feldman, Howard H, Prof, Jacova, Claudia, PhD, Hampel, Harald, Prof, Molinuevo, José Luis, MD, Blennow, Kaj, MD, DeKosky, Steven T, Prof, Gauthier, Serge, Prof, Selkoe, Dennis, Prof, Bateman, Randall, MD, Cappa, Stefano, MD, Crutch, Sebastian, PhD, Engelborghs, Sebastiaan, MD, Frisoni, Giovanni B, Prof, Fox, Nick C, MD, Galasko, Douglas, Prof, Habert, Marie-Odile, MD, Jicha, Gregory A, MD, Nordberg, Agneta, MD, Pasquier, Florence, Prof, Rabinovici, Gil, MD, Robert, Philippe, Prof, Rowe, Christopher, MD, Salloway, Stephen, Prof, Sarazin, Marie, Prof, Epelbaum, Stéphane, MD, de Souza, Leonardo C, MD, Vellas, Bruno, Prof, Visser, Pieter J, MD, Schneider, Lon, Prof, Stern, Yaakov, Prof, Scheltens, Philip, Prof, Cummings, Jeffrey L, Prof

“…Summary In the past 8 years, both the International Working Group (IWG) and the US National Institute on Aging–Alzheimer's Association have contributed…”
Get full text

Sortilin-Mediated Endocytosis Determines Levels of the Frontotemporal Dementia Protein, Progranulin by Hu, Fenghua, Padukkavidana, Thihan, Vægter, Christian B., Brady, Owen A., Zheng, Yanqiu, Mackenzie, Ian R., Feldman, Howard H., Nykjaer, Anders, Strittmatter, Stephen M.

“…The most common inherited form of Frontotemporal Lobar Degeneration (FTLD) known stems from Progranulin ( GRN) mutation and exhibits TDP-43 plus ubiquitin…”
Get full text

Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial by Gauthier, Serge, Prof, Feldman, Howard H, Prof, Schneider, Lon S, Prof, Wilcock, Gordon K, Prof, Frisoni, Giovanni B, Prof, Hardlund, Jiri H, MD, Moebius, Hans J, MD, Bentham, Peter, MBChB, Kook, Karin A, PhD, Wischik, Damon J, PhD, Schelter, Bjoern O, Prof, Davis, Charles S, PhD, Staff, Roger T, PhD, Bracoud, Luc, MSc, Shamsi, Kohkan, MD, Storey, John M D, Prof, Harrington, Charles R, PhD, Wischik, Claude M, Prof

“…Summary Background Leuco-methylthioninium bis(hydromethanesulfonate; LMTM), a stable reduced form of the methylthioninium moiety, acts as a selective inhibitor…”
Get full text

The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease by Albert, Marilyn S, DeKosky, Steven T, Dickson, Dennis, Dubois, Bruno, Feldman, Howard H, Fox, Nick C, Gamst, Anthony, Holtzman, David M, Jagust, William J, Petersen, Ronald C, Snyder, Peter J, Carrillo, Maria C, Thies, Bill, Phelps, Creighton H

“…Abstract The National Institute on Aging and the Alzheimer’s Association charged a workgroup with the task of developing criteria for the symptomatic…”
Get full text

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria by Dubois, Bruno, MD, Feldman, Howard H, MD, Jacova, Claudia, PhD, DeKosky, Steven T, MD, Barberger-Gateau, Pascale, MD, Cummings, Jeffrey, MD, Delacourte, André, PhD, Galasko, Douglas, MD, Gauthier, Serge, MD, Jicha, Gregory, MD, Meguro, Kenichi, MD, O'Brien, John, MD, Pasquier, Florence, MD, Robert, Philippe, MD, Rossor, Martin, MD, Salloway, Steven, MD, Stern, Yaakov, PhD, Visser, Pieter J, MD, Scheltens, Philip, MD

“…Summary The NINCDS–ADRDA and the DSM-IV-TR criteria for Alzheimer's disease (AD) are the prevailing diagnostic standards in research; however, they have now…”
Get full text

Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance by Ewers, Michael, Walsh, Cathal, Trojanowski, John Q, Shaw, Leslie M, Petersen, Ronald C, Jack, Clifford R, Feldman, Howard H, Bokde, Arun L.W, Alexander, Gene E, Scheltens, Philip, Vellas, Bruno, Dubois, Bruno, Weiner, Michael, Hampel, Harald

“…Abstract The current study tested the accuracy of primary MRI and cerebrospinal fluid (CSF) biomarker candidates and neuropsychological tests for predicting…”
Get full text

Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup by Sperling, Reisa A, Jack, Clifford R, Black, Sandra E, Frosch, Matthew P, Greenberg, Steven M, Hyman, Bradley T, Scheltens, Philip, Carrillo, Maria C, Thies, William, Bednar, Martin M, Black, Ronald S, Brashear, H. Robert, Grundman, Michael, Siemers, Eric R, Feldman, Howard H, Schindler, Rachel J

“…Abstract Amyloid imaging related abnormalities (ARIA) have now been reported in clinical trials with multiple therapeutic avenues to lower amyloid-β burden in…”
Get full text

Nonpharmacological therapies in Alzheimer's disease: a systematic review of efficacy by Olazarán, Javier, Reisberg, Barry, Clare, Linda, Cruz, Isabel, Peña-Casanova, Jordi, Del Ser, Teodoro, Woods, Bob, Beck, Cornelia, Auer, Stefanie, Lai, Claudia, Spector, Aimee, Fazio, Sam, Bond, John, Kivipelto, Miia, Brodaty, Henry, Rojo, José Manuel, Collins, Helen, Teri, Linda, Mittelman, Mary, Orrell, Martin, Feldman, Howard H, Muñiz, Ruben

“…Nonpharmacological therapies (NPTs) can improve the quality of life (QoL) of people with Alzheimer's disease (AD) and their carers. The objective of this study…”
Get more information

Evaluation of bumetanide as a potential therapeutic agent for Alzheimer’s disease by Boyarko, Ben, Podvin, Sonia, Greenberg, Barry, Momper, Jeremiah D., Huang, Yadong, Gerwick, William H., Bang, Anne G., Quinti, Luisa, Griciuc, Ana, Kim, Doo Yeon, Tanzi, Rudolph E., Feldman, Howard H., Hook, Vivian

“…Therapeutics discovery and development for Alzheimer’s disease (AD) has been an area of intense research to alleviate memory loss and the underlying pathogenic…”
Get full text

Synaptic dysfunction in progranulin-deficient mice by Petkau, Terri L, Neal, Scott J, Milnerwood, Austen, Mew, Ada, Hill, Austin M, Orban, Paul, Gregg, Jenny, Lu, Ge, Feldman, Howard H, Mackenzie, Ian R.A, Raymond, Lynn A, Leavitt, Blair R

“…Abstract Progranulin haploinsufficiency is a common cause of familial frontotemporal dementia (FTD), but the role of progranulin in the brain is poorly…”
Get full text

Protocol for a seamless phase 2A-phase 2B randomized double-blind placebo-controlled trial to evaluate the safety and efficacy of benfotiamine in patients with early Alzheimer's disease (BenfoTeam) by Feldman, Howard H, Luchsinger, José A, Léger, Gabriel C, Taylor, Curtis, Jacobs, Diane M, Salmon, David P, Edland, Steven D, Messer, Karen, Revta, Carolyn, Flowers, Sarah A, Jones, Kerry S, Koulman, Albert, Yarasheski, Kevin E, Verghese, Philip B, Venkatesh, Venky, Zetterberg, Henrik, Durant, January, Lupo, Jody-Lynn, Gibson, Gary E

“…Benfotiamine provides an important novel therapeutic direction in Alzheimer's disease (AD) with possible additive or synergistic effects to amyloid targeting…”
Get full text

Multidomain trials to prevent dementia: addressing methodological challenges by Montero-Odasso, Manuel, Zou, G Y, Kamkar, Nellie, Feldman, Howard H, Belleville, Sylvie, Chertkow, Howard, Nygaard, Haakon B, Son, Surim, Speechley, Mark

“…Abstract Background Multidomain trials to prevent dementia by simultaneously targeting multiple risk factors with non-pharmacological lifestyle interventions…”
Get full text

Adaptive crossover designs for assessment of symptomatic treatments targeting behaviour in neurodegenerative disease: a phase 2 clinical trial of intranasal oxytocin for frontotemporal dementia (FOXY) by Finger, Elizabeth, Berry, Scott, Cummings, Jeffrey, Coleman, Kristy, Hsiung, Robin, Feldman, Howard H, Boxer, Adam

“…There are currently no treatments for empathy deficits in neuropsychiatric disorders. Acute administration of the hormone oxytocin has been associated with…”
Get full text

Potential for misclassification of mild cognitive impairment: a study of memory scores on the Wechsler Memory Scale-III in healthy older adults by Brooks, Brian L, Iverson, Grant L, Holdnack, James A, Feldman, Howard H

“…The psychometric criterion of mild cognitive impairment (MCI) generally involves having an unusually low score on memory testing (i.e., -1.5 SDs). However,…”
Get more information

Diagnosis and treatment of dementia: 2. Diagnosis by Feldman, Howard H, Jacova, Claudia, Robillard, Alain, Garcia, Angeles, Chow, Tiffany, Borrie, Michael, Schipper, Hyman M, Blair, Mervin, Kertesz, Andrew, Chertkow, Howard

“…Dementia can now be accurately diagnosed through clinical evaluation, cognitive screening, basic laboratory evaluation and structural imaging. A large number…”
Get full text

A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer's Disease by Galasko, Douglas, Farlow, Martin R, Lucey, Brendan P, Honig, Lawrence S, Elbert, Donald, Bateman, Randall, Momper, Jeremiah, Thomas, Ronald G, Rissman, Robert A, Pa, Judy, Aslanyan, Vahan, Balasubramanian, Archana, West, Tim, Maccecchini, Maria, Feldman, Howard H

“…Amyloid beta protein (Aβ) is a treatment target in Alzheimer's Disease (AD). Lowering production of its parent protein, APP, has benefits in preclinical…”
Get full text

Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study by Feldman, Howard H, MD, Ferris, Steven, PhD, Winblad, Bengt, MD, Sfikas, Nikolaos, PhD, Mancione, Linda, BA, He, Yunsheng, PhD, Tekin, Sibel, MD, Burns, Alistair, MD, Cummings, Jeffrey, MD, del Ser, Teodoro, MD, Inzitari, Domenico, MD, Orgogozo, Jean-Marc, MD, Sauer, Heinrich, MD, Scheltens, Philip, MD, Scarpini, Elio, MD, Herrmann, Nathan, MD, Farlow, Martin, MD, Potkin, Steven, MD, Charles, H Cecil, PhD, Fox, Nick C, MD, Lane, Roger, MD

“…Summary Objective To assess the effect of rivastigmine in patients with mild cognitive impairment (MCI) on the time to clinical diagnosis of Alzheimer's…”
Get full text

Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder by Coric, Vladimir, Feldman, Howard H., Oren, Dan A., Shekhar, Anantha, Pultz, Joseph, Dockens, Randy C., Wu, Xiaoling, Gentile, Kimberly A., Huang, Shu-Pang, Emison, Eileen, Delmonte, Terrye, D'Souza, Bernadette B., Zimbroff, Daniel L., Grebb, Jack A., Goddard, Andrew W., Stock, Elyse G.

“…Background: Antagonism of corticotropin‐releasing factor (CRF) receptors has been hypothesized as a potential target for the development of novel anxiolytics…”
Get full text